Rocket Pharmaceuticals (RCKT) Return on Capital Employed (2015 - 2026)

Rocket Pharmaceuticals has disclosed Return on Capital Employed across 12 years of filings, most recently posting 76.15% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 76.15%, down 1793.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 76.15% (down 1793.0% YoY), and the FY2025 annual result was 58.1%, down 414.0% from the prior year.
• Return on Capital Employed came in at 76.15% for Q1 2026 at Rocket Pharmaceuticals, down from 72.64% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 37.41% in Q1 2022 to a low of 76.15% in Q1 2026.
• The 5-year median for Return on Capital Employed is 56.95% (2023), against an average of 57.98%.
• Across the five-year window, Return on Capital Employed tumbled 1860 bps in 2024 and soared 310 bps in 2025, its largest moves.
• Rocket Pharmaceuticals' Return on Capital Employed stood at 50.37% in 2022, then increased by 3 bps to 48.62% in 2023, then slumped by 34 bps to 65.05% in 2024, then decreased by 12 bps to 72.64% in 2025, then fell by 5 bps to 76.15% in 2026.
• The last three Return on Capital Employed figures came in at 76.15% (Q1 2026), 72.64% (Q4 2025), and 68.94% (Q3 2025), per Business Quant data.